Abstract

Simultaneous Transfemoral Transcatheter Aortic Valve Replacement of a Native Aortic Valve and Transapical Transcatheter Mitral Valve-in-Valve Replacement

With Transcatheter Aortic Valve Replacement (TAVR) revolutionizing the treatment of high-surgical risk patients with severe aortic stenosis, Transcatheter Mitral Valve Replacement (TMVR) is slowly emerging as an off-label therapy for severe mitral valve disease. A case of 70-year-old female with recurrent history of congestive heart failure has been described. This case demonstrates the simultaneous TAVR and off-label VIV TMVR is a reasonable alternative for highrisk surgical patients with stenotic native and failing bioprosthetic valves.


Author(s):

Tanya Doctorian, Daniel Serna, Blanding Jones, Arti Choure1, Ramdas Pai4, Eric Chou1 and William Mosley II1



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • World Heart Congress
    April 19-20, 2018 Amsterdam, Netherlands
  • Cardiovascular Medicine and Cardiac Surgery
    July 05-06, 2018 Berlin, Germany
  • International Conference on Cardiovascula r Imaging
    July 11-12, 2018 Sydney,Australia
Flyer image

Abstracted/Indexed in

  • Index Copernicus
  • Google Scholar
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat